Roth Daniel B, Chieh Janet, Spirn Marc J, Green Stuart N, Yarian David L, Chaudhry Nauman A
Retina Vitreous Center, Department of Ophthalmology, University of Medicine and Dentistry of New Jersey, New Brunswick 08901, USA.
Arch Ophthalmol. 2003 Sep;121(9):1279-82. doi: 10.1001/archopht.121.9.1279.
Intravitreal injection of triamcinolone has been advocated to treat exudative macular diseases such as macular edema and choroidal neovascularization.
To describe 7 patients who developed a clinical picture simulating endophthalmitis after intravitreal triamcinolone injection.
Intravitreal triamcinolone injections were performed to treat refractory cystoid macular edema or diffuse macular edema associated with diabetic retinopathy, macular pucker, branch retinal vein occlusion, or pseudophakia. One patient received an injection in an attempt to treat exudation associated with occult choroidal neovascularization.
Preinjection visual acuity ranged from 20/50 to 20/400. An extensive inflammatory response developed 1 to 2 days after injection in all 7 eyes. Five eyes had previously undergone vitrectomy. Four eyes had a layered hypopyon. All 7 eyes had an anterior chamber cellular reaction and vitritis. Visual acuity ranged from 20/400 to hand movements. The first 6 patients were treated for presumed endophthalmitis with vitreous cultures and intravitreal injections of antibiotics. All 6 cultures were negative for any organisms, and the eyes resolved their inflammatory response, with recovery to preinjection visual acuity or better. The seventh patient was treated with topical prednisolone without antibiotic therapy, and the inflammation resolved, with resolution of the macular edema seen before the intravitreal triamcinolone injection.
It may be appropriate to closely observe noninfectious, toxic endophthalmitis in patients treated with intravitreal triamcinolone before assuming it to be infectious, especially in the absence of eye pain.
玻璃体内注射曲安奈德已被推荐用于治疗渗出性黄斑疾病,如黄斑水肿和脉络膜新生血管形成。
描述7例在玻璃体内注射曲安奈德后出现类似眼内炎临床表现的患者。
进行玻璃体内曲安奈德注射以治疗难治性黄斑囊样水肿或与糖尿病视网膜病变、黄斑皱襞、视网膜分支静脉阻塞或人工晶状体相关的弥漫性黄斑水肿。1例患者为尝试治疗与隐匿性脉络膜新生血管形成相关的渗出而接受注射。
注射前视力范围为20/50至20/400。所有7只眼在注射后1至2天出现广泛的炎症反应。5只眼此前已接受玻璃体切除术。4只眼有分层的前房积脓。所有7只眼均有前房细胞反应和玻璃体炎。视力范围为20/400至手动。前6例患者因疑似眼内炎接受玻璃体培养和玻璃体内注射抗生素治疗。所有6次培养均未发现任何微生物,眼部炎症反应消退,视力恢复至注射前水平或更好。第7例患者接受局部泼尼松龙治疗,未使用抗生素,炎症消退,玻璃体内注射曲安奈德前出现的黄斑水肿也消退。
在玻璃体腔内注射曲安奈德治疗的患者中,在假定为感染性眼内炎之前,密切观察非感染性、中毒性眼内炎可能是合适的,尤其是在没有眼痛的情况下。